Back to Authors

Ghori, Razi

https://orcid.org/0009-0004-3095-8612

A5049602816 | I1285764155

Mayo Clinic

Merck & Co., Inc., Rahway, NJ, USA (United States)

Citations 3

P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES

HemaSphere | August 21, 2023 | Volume: 7 | Issue: S3 | Pages: e7809236

10.1097/01.hs9.0000969416.78092.36

Updated follow‐up of BELLWAVE‐001: an open‐label, single‐arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B‐cell malignancies

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 565-567

10.1002/hon.3164_423

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7004-7006

10.1182/blood-2022-163596